Piperacillin-tazobactam: Difference between revisions
From IDWiki
(Created page with "== Background == === Clinical Breakpoints === {| class="wikitable" ! rowspan="2" |Species ! rowspan="2" |ECV (μg/mL) ! colspan="4" |Breakpoints (μg/mL) ! colspan="4" |Break...") |
No edit summary |
||
| Line 1: | Line 1: | ||
| − | == |
+ | ==Background== |
| − | === |
+ | ===Clinical Breakpoints=== |
{| class="wikitable" |
{| class="wikitable" |
||
! rowspan="2" |Species |
! rowspan="2" |Species |
||
! rowspan="2" |ECV (μg/mL) |
! rowspan="2" |ECV (μg/mL) |
||
| − | ! colspan=" |
+ | ! colspan="3" |Breakpoints (μg/mL) |
| − | ! colspan=" |
+ | ! colspan="3" |Breakpoints (mm) |
|- |
|- |
||
!S |
!S |
||
!I |
!I |
||
| − | !SDD |
||
!R |
!R |
||
!S |
!S |
||
!I |
!I |
||
| − | !SDD |
||
!R |
!R |
||
|- |
|- |
||
| Line 21: | Line 19: | ||
|≤16/4 |
|≤16/4 |
||
|32/4-64/4 |
|32/4-64/4 |
||
| − | |— |
||
|≥128/4 |
|≥128/4 |
||
|≥21 |
|≥21 |
||
|18-20 |
|18-20 |
||
| − | |— |
||
|≤17 |
|≤17 |
||
|- |
|- |
||
| Line 32: | Line 28: | ||
|≤16/4 |
|≤16/4 |
||
|32/4-64/4 |
|32/4-64/4 |
||
| − | |— |
||
|≥128/4 |
|≥128/4 |
||
|≥21 |
|≥21 |
||
|15-20 |
|15-20 |
||
| − | |— |
||
|≤14 |
|≤14 |
||
|- |
|- |
||
| Line 43: | Line 37: | ||
|≤16/4 |
|≤16/4 |
||
|32/4-64/4 |
|32/4-64/4 |
||
| − | |— |
||
|≥128/4 |
|≥128/4 |
||
|≥21 |
|≥21 |
||
|18-20 |
|18-20 |
||
| − | |— |
||
|≤17 |
|≤17 |
||
|- |
|- |
||
| Line 54: | Line 46: | ||
|≤16/4 |
|≤16/4 |
||
|32/4-64/4 |
|32/4-64/4 |
||
| − | |— |
||
|≥128/4 |
|≥128/4 |
||
| − | | |
||
| |
| |
||
| |
| |
||
| Line 65: | Line 55: | ||
|≤16/4 |
|≤16/4 |
||
|32/4-64/4 |
|32/4-64/4 |
||
| − | |— |
||
|≥128/4 |
|≥128/4 |
||
| − | | |
||
| |
| |
||
| |
| |
||
| Line 75: | Line 63: | ||
| |
| |
||
|≤1/4 |
|≤1/4 |
||
| − | |— |
||
|— |
|— |
||
|≥2/4 |
|≥2/4 |
||
|≥21 |
|≥21 |
||
| − | |— |
||
|— |
|— |
||
|— |
|— |
||
|- |
|- |
||
|Gram-positive bacteria |
|Gram-positive bacteria |
||
| − | | colspan=" |
+ | | colspan="7" |susceptibility predicted by [[penicillin]] |
|} |
|} |
||
[[Category:Β-lactams]] |
[[Category:Β-lactams]] |
||
Revision as of 11:25, 13 September 2020
Background
Clinical Breakpoints
| Species | ECV (μg/mL) | Breakpoints (μg/mL) | Breakpoints (mm) | ||||
|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | ||
| Enterobacterales | ≤16/4 | 32/4-64/4 | ≥128/4 | ≥21 | 18-20 | ≤17 | |
| Pseudomonas aeruginosa | ≤16/4 | 32/4-64/4 | ≥128/4 | ≥21 | 15-20 | ≤14 | |
| Acinetobacter species | ≤16/4 | 32/4-64/4 | ≥128/4 | ≥21 | 18-20 | ≤17 | |
| Other non-Enterobacterales | ≤16/4 | 32/4-64/4 | ≥128/4 | ||||
| Anaerobes | ≤16/4 | 32/4-64/4 | ≥128/4 | ||||
| Haemophilus influenzae and Haemophilus parainfluenzae | ≤1/4 | — | ≥2/4 | ≥21 | — | — | |
| Gram-positive bacteria | susceptibility predicted by penicillin | ||||||
